Dr Jonny White explains the results of a 10 year prospective study into disease modifying drugs treatments for pwMS.
A study appears to have found a link between multiple sclerosis and lower blood levels of VK2, a fat-soluble molecule.
New research has found that existing guidelines on recommended vitamin D intake may be dangerously low.
A new treatment called Ocrelizumab has been found to have a positive effect on RRMS, but the nature of the market could mean it stays an expensive drug.
Tysabri is a disease-modifying drug currently given by intravenous infusion every 4 weeks and is commonly prescribed for the treatment of very active MS.
A new study has found evidence that smoking negatively impacts people with relapsing-remitting multiple sclerosis (RRMS) who are receiving interferon treatment.